Gemcitabine CAS 95058-81-4 gencitabine base

Place of Origin: Sichuan,China (Mainland)
Brand: MOSINTER
Formula: C9H11F2N3O4
Mol. mass: 263.198 g/mol
Content: >99%

inquiry

skype basketAdd to Basket  Edit

Share |

Product Description

Payment & Shipping Terms Supply Capacity
Payment Terms:L/C, T/T, WUProduction Capacity:12T/Year
Min. Order:3 KilogramPacking:According to customer...
Means of Transport:Ocean, Air, LandDelivery Date:within 7 days

Gemcitabine (CAS: 95058-81-4)


Item

Index

Molecular Formula

C9H11F2N3O4

Molecular Weight

263.199

Specification

CP/USP/EP

Content

≥98%

Pharmacology

Chemically gemcitabine is a nucleoside analog in which the hydrogen atoms on the 2' carbon of deoxycytidine are replaced by fluorine atoms.

As with fluorouracil and other analogues of pyrimidines, the triphosphate analogue of gemcitabine replaces one of the building blocks of nucleic acids, in this case cytidine, during DNA replication. The process arrests tumor growth, as only one additional nucleoside can be attached to the "faulty" nucleoside, resulting in apoptosis.

Another target of gemcitabine is the enzyme ribonucleotide reductase (RNR). The diphosphate analogue binds to RNR active site and inactivates the enzyme irreversibly. Once RNR is inhibited, the cell cannot produce the deoxyribonucleotides required for DNA replication and repair, and cell apoptosis is induced.


Administration

Gemcitabine is administered by the intravenous route, since it is extensively metabolized by the gastrointestinal tract. Dose ranges from 1-1.2 g/m2 of body surface area according to type of cancer treated.


Indications

Gemcitabine is used in various carcinomas: non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer. It is being investigated for use in esophageal cancer, and is used experimentally in lymphomas and various other tumor types. Gemcitabine represents an advance in pancreatic cancer care[citation needed]. It is also not as debilitating as some other forms of chemotherapy.

A study reported in the Journal of the American Medical Association in 2007 suggested that gemcitabine showed benefit in patients with pancreatic cancer who were felt to have successful tumor resections.

Gemcitabine became first line treatment for bladder cancer Stage 4 with metastases in combination with cisplatin after a study in 2000 with 405 patients showed similar efficacy but less toxicity compared to the former MVAC regimen. This new CG-regimen involves taking cisplatin on day 2 and taking gemcitabine on days 1, 8, and 15. In July 2006 the FDA approved gemcitabine for use with carboplatin in the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based (e.g., carboplatin or cisplatin) therapy. Neutropenia was the most commonly reported adverse effect (90% of patients). Other serious adverse effects were mostly hematologic. Gemcitabine was recently also investigated for advanced cancer of the biliary tract and gallbladder and was found to have a modest effect on the tumor when combined with cisplatin (NEJM 2010).


GemCarbo chemotherapy for lung cancer

GemCarbo chemotherapy, consisting of a combination of gemcitabine and carboplatin, is used to treat several different types of cancer, but is most commonly used to treat lung cancer.


Side effects

  • Flu-like symptoms such as muscle pain, fever, headache, chills, and fatigue

  • Fever (within 6–12 hours of first dose)

  • Fatigue

  • Nausea (mild)

  • Vomiting

  • Poor appetite

  • Skin rash

  • Allergic reaction

  • Diarrhea

  • Weakness

  • Hair loss

  • Mouth sores

  • Difficulty sleeping

  • Shortness of breath


Category: Antineoplastic Drugs API

Related Category: Other Pharmaceutical API  Veterinary Medicine API  Diagnostic Agents API  Vitamin Preparation API  Psychotropic Drugs API 


«
Offline Showroom in USA
QR Code